newsfilter
← Latest News
GlobeNewswire·

MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results

  • MapLight Therapeutics completed enrollment in the Phase 2 ZEPHYR trial for ML-007C-MA to treat schizophrenia
  • The final patient visit was completed for the Phase 2 IRIS trial evaluating ML-004 for autism spectrum disorder
  • Topline results from both Phase 2 trials are expected by mid-August 2026
  • The ZEPHYR trial randomized 307 inpatient adults with schizophrenia to receive placebo, 210/3 mg twice daily, or 330/6 mg once daily doses
  • The IRIS trial randomized 161 participants, including over 100 adolescents aged 12-17, with autism spectrum disorder
  • Primary endpoints for the trials involve changes in PANSS total score for ZEPHYR by Week 5 & ABI-Social Communication Domain Score for IRIS by Week 12